This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
by Urmimala Biswas
RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.
RMD Stock Likely to Benefit From the New Brand Evolution Strategy
by Zacks Equity Research
In another major brand update, Resmed is likely to unify all the brands under one identity.
Should You Continue to Retain STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
Investors continue to keep an eye on STE due to its promising Healthcare arm and AST segment's prospects.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Indrajit Bandyopadhyay
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock
VEEV Stock Gains Following Latest Availability of HCP Access Data
by Zacks Equity Research
Veeva Systems aims to provide immediate value for commercial operations and data analytics teams via CRM Pulse, which provides quarterly HCP access data.
Is it Worth Adding ResMed Stock to Your Portfolio Now?
by Zacks Equity Research
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Zacks.com featured highlights include Taiwan, Tapestry, ABM Industries, Vertiv and ResMed
by Zacks Equity Research
Taiwan, Tapestry, ABM Industries, Vertiv and ResMed have been highlighted in this Screen of The Week article.
5 Best Dividend Growth Stocks to Buy Amid Trade War Fears
by Sweta Killa
Investors searching for safe and consistent income amid global trade war fears. Dividend growth stocks like TSM, TPR, ABM, VRT and RMD are solid choices.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation
by Zacks Equity Research
Veeva Systems aims to enable advanced automation, including AI, for the life sciences industry via innovative technology and deep applications on the Veeva Vault Platform.
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
IART delivers better-than-expected earnings in the fourth quarter of 2024.
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises
by Zacks Equity Research
Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes
by Zacks Equity Research
TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.
Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract
by Zacks Equity Research
CHE's earnings and revenues beat estimates in the fourth quarter of 2024.
XRAY Q4 Earnings & Revenues Miss Estimates, Gross Margin Down
by Zacks Equity Research
DENTSPLY SIRONA's fourth-quarter results showcase dismal segmental performance with declining adjusted operating income.
AVNS Stock Gains Post Q4 Earnings & Revenue Beat, Margins Contract
by Zacks Equity Research
Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss
by Zacks Equity Research
Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.
EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges
by Zacks Equity Research
Continued strength in Managed Care aids National Vision's fourth-quarter 2024 performance.
MMSI Stock Gains in Pre-Market Post Q4 Earnings Beat, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the fourth quarter of 2024.